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A b s t r a c t
Introduction: The primary goal of lipid-lowering therapy is the attainment of
low-density lipoprotein cholesterol (LDL-C) target levels.
Material and methods: The MULTI GAP (MULTI Goal Attainment Problem) 2010
is a part of surveys started a few years ago, in which the lipid results of 1540
patients treated by general practitioners (GPs) and specialists were measured.
The data were compared to the results of similar studies involving 15,580
patients between 2004 and 2009.
Results: In 2010 the mean LDL-C level (± SD) of patients treated by GPs was
found to be 3.01 ±1.0 mmol/l. The target of 2.50 mmol/l was achieved by 32%,
with a mean LDL-C level of 2.84 ±1.0 mmol/l and an achievement rate of 39%
in patients treated by specialists. The results of comparisons starting from 2004
showed a marked improvement every year in the beginning, but in the last 
3 years stagnation was observed. In 2010 in addition to the MULTI GAP main
study, a group of physicians took part in special training called the Plus Program.
As a result of this, the LDL-C level was 0.18 mmol/l lower in 114 of the GPs’
patients (p = 0.088) and 0.27 mmol/l (p < 0.0001) lower in 313 of the specialists’
patients, with a significantly better, 42% (p = 0.045) and 50% (p = 0.001), goal
attainment rate, respectively. 
Conclusions: The 2010 MULTI GAP study shows that the quality of lipid-lowering
therapy in Hungary seems to be in stagnation. The results of the PLUS Program
suggest that continuous training of doctors is the key to further improvement. 
Key words: prevention, risk factors, hypercholesterolaemia, LDL cholesterol.
Introduction
Despite the clear improvement in recent years, cardiovascular disease
(CVD) continues to be the leading cause of death in mortality statistics [1].
Coronary heart disease (CHD) is a global epidemic and its prevention is
one of the biggest challenges in contemporary medicine. The European
Heart Health Charter highlights that beside the increasing funding spent
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for the treatment of CVD in developed countries,
a stronger emphasis should be placed on
prevention [2, 3]. The recommendations and the
cardiovascular prevention in daily practice should
be bridged as soon as possible [4].
It is a well-known fact that the main reasons
leading to the development of CHD are related to
lifestyle. This is supported by the INTERHEART study
carried out in 52 countries which proved that
several well-defined and reversible risk factors are
responsible for 90% of heart attacks [5]. One of the
most important risk factors is hyperlipidaemia.
Lipid-lowering therapy has outstanding importance
in the treatment of high-risk patients. What is the
situation of lipid-lowering therapy in Hungary and
how could the quality of treatment be improved
further? Based on the results of surveys carried out
systematically since 2004 by general practitioners
(GPs) and specialists among high-risk patients, the
frequencies of target level attainment and
alterations of lipid-lowering treatments are
comparable. Besides presenting these results and
those of MULTI GAP (MULTI Goal Attainment
Problem) 2010, the recent data are compared to
those observed in patients of a group of physicians
who received special training.
Material and methods
The trends in lipid-lowering treatment were
studied using surveys (CEL Program 2004 and 2005,
KONSZENZUS-CEL Program 2006, REALITY 2004 and
2007 studies, MULTI GAP 2008 and 2009) perfor -
med on high cardiovascular risk patients of GPs and
specialists in Hungary. From the period between
2004 and 2008, the data of 12 317 [6], and from
MULTI GAP 2009 those of 3563 patients [7] were
processed.
In the MULTI-GAP 2010 study we analysed data
and treatment strategies of 1540 patients from 136
specialists and 47 GPs (10-15 patients per physician
were enrolled) using a structured questionnaire.
The previous publication on 2010 data [8] did not
separate the patients of the main study from those
of the Plus Program, and in this study we used only
the data of the patients being conformed with the
former publications. The patients gave their consent
to participate; the study was conducted in
accordance with the Declaration of Helsinki and
ICH-GCP (International Conference on Harmo -
nisation – Good Clinical Practice). 
Out of physicians participating in MULTI GAP
2010, 26 specialists and 9 GPs also took part in the
PLUS Program with 397 and 117 patients,
respectively. In this framework, these colleagues
received special education related to lipid treatment,
attended lectures on the guidelines of the
Hungarian consensus conference [9], and received
written material related to this topic as well. They
were supplied with a calculator to determine the
low-density lipoprotein cholesterol (LDL-C) level and
also with software to analyse target level achie -
vements which showed the proportion of treated
patients attaining the target level in their whole
practice, thus helping therapy and drawing
attention to the insufficiencies of lipid-lowering
therapy.
The whole MULTI GAP patient group (including
the Plus Program patients) included 197 cases of
unstable angina, 590 cases of previous myocardial
infarction, 275 cases of vascular operation due to
peripheral arterial disease, 432 cases of stroke and
275 of transient ischaemic attack, 924 diabetic
patients and 1770 with hypertension. The existence
and extent of smoking, as well as the sex, age, body
mass index and waist circumference were recorded.
842 women and 1125 men participated in the study;
their mean age was 64.4 ±10 years. The doctors also
estimated patient compliance based on frequency
of statin prescription, the patients’ knowledge and
questioning the patients.
The risk classification of patients was performed
according to the 4th Hungarian Cardiovascular
Consensus Conference recommendations [9]. All
patients belonged to the high cardiovascular risk
category, and because they also had a history of
vascular events and/or were diabetic, they had 
LDL-C targets of ≤ 2.50 mmol/l.
Statistical analysis 
For categorical variables we used frequencies of
valid cases. For continuous variables means and
medians are presented. Significance tests were
performed by χ2 test for categorical and by ANOVA
for continuous variables (with Fisher's least
significant difference test method for multiple
comparisons). Asymmetric 2-sided scores were
considered. Values of p (two-tailed) below 0.05 were
accepted as significant. All statistical analyses were
performed by SPSS.
Results
The MULTI GAP 2010 main study involved 1540
patients. The GPs’ patients had a mean LDL-C level
(± SD) of 3.01 ±1.0 mmol/l, while those of the
specialists had 2.84 ±1.0 mmol/l. Figure 1 demons -
tra tes changes of LDL-C level between 2004 and
2010, showing a decrease of 0.77 mmol/l for
patients treated by GPs whereas in patients treated
by specialists a decrease of 0.50 mmol/l could be
observed during this 7-year period. In 2010, 32% of
the GPs' patients achieved the 2.50 mmol/l LDL-C
target value, while for patients treated by specia -
lists the corresponding proportion was 39%; Figu -
res 2 and 3 show changes in rates of patients
achieving the target levels. In addition to the MULTI
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GAP main study, a group of doctors underwent
special training in 2010, called the Plus Program.
Table I shows the mean LDL-C level of the 427
patients treated by GPs and specialists and the
percentage of them achieving the level of 2.50
mmol/l. The GP patients experienced a reduction
of 0.18 mmol/l in their mean LDL-C level, while
those of specialists had a decrease of 0.27 mmol/l.
Accordingly, a significant (10 and 11%) increase
occurred in the 2.50 mmol/l LDL-C attainment rate
in both GPs’ and specialists’ patients (increasing to
42 and 50%, respectively). Table II presents the
mean body mass index values and the occurrence
of hypertension, smoking and diabetes in the MULTI
GAP 2010 basic study and the PLUS Program in the
patient groups treated by GPs and specialists. Also
shown are the values of significance between the
MULTI GAP 2010 study and the Plus Program and
between the GPs’ and specialists’ patients. 
In our study we separated male and female
groups when analysing the mean LDL-C levels.
These, along with the mean BMI values, and the
occurrence of hypertension, smoking and diabetes
in the two genders are presented in Table III. The
LDL-C in women was 6.2% (0.17 mmol/l) higher
than the value considering all patients, and similar
rates were found among male and female patients
of physicians participating and not participating in
the Plus Program (0.15 and 0.18 mmol/l difference,
respectively). The 2010 MULTI GAP study also
evaluated the physicians' lipid-lowering medical
treatment compliance. This was based on ques -
tioning the patient and the frequency of drug
prescriptions, and the result was given in percen -
tage. Four groups were formed based on com -
pliance: 70% or below, 71-80%, 81-90% and over
90% of patients were considered cooperative in
each group, respectively. The 2.50 mmol/l LDL-C
target achievement rate was 24, 31, 39 and 41%,
respectively (Figure 4).
We examined what doses of statin were applied
in the patients reaching or not reaching the target.
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Figure 1. Change in mean LDL-cholesterol levels of
high cardiovascular risk patients treated by GPs and
specialists, over the years
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Figure 3. Changes in the ratio of patients reaching
the target 2.5 mmol/l of LDL-cholesterol level treated
by specialists over the last years
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Figure 2. Changes in the ratio of patients reaching
the target 2.5 mmol/l of LDL-cholesterol level treated
by GP’s over the last years
GPs Specialists
Patient LDL cholesterol Target Patient LDL cholesterol Target
number level [mmol/l] achieve- number level [mmol/l] achieve-
ment [%] ment [%]
MULTI GAP 2010 397 3.01 ±1.00 32 1143 2.84 ±0.99 39
PLUS Program 114 2.83 ±0.95 42 313 2.57 ±0.90 50
p = 0.088 p = 0.045 p < 0.0001 p = 0.001
Table I. The mean LDL cholesterol and the achie vement rate of 2.50 mmol/l target LDL cholesterol in the MULTI GAP
2010 basic study and PLUS Program
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To compare the efficacy of different statins we
calculated simvastatin equivalent doses [10, 11].
Those who did not reach the 2.50 mmol/l target
level had a daily simvastatin dose of 39.4 mg, while
those who achieved the target were on 42.2 mg
(non-significant difference, p = 0.11). During the
treatment the doctors also applied ezetimibe as
combination therapy in order to achieve the target
in addition to statins. The rate of administration of
combination therapy was 10% in the MULTI 
GAP main study and 22% in the PLUS Program 
(p < 0.001). The application of combination therapy
significantly helped to achieve the 2.50 mmol/l 
LDL-C target in both MULTI GAP 2010 and the PLUS
Program (p < 0.001) (Figure 5).
Discussion
The results of the INTERHEART study showed
that in 90% of cases, well-defined risk factors are
responsible for the development of myocardial
GPs Specialists Value of p
Body mass index [kg/m2]
MULTI GAP 2010 28.8 ±4.9 29.2 ±5.0 0.152
PLUS Program 28.9 ±5.4 29.4 ±4.8 0.399
p = 0.763 p = 0.537
Hypertension [%]
MULTI GAP 2010 93 89 0.038
PLUS Program 82 94 0.000
p = 0.001 p = 0.011
Smoking [%]
MULTI GAP 2010 28 28 0.782
PLUS Program 37 31 0.228
p = 0.060 p = 0.439
Diabetes mellitus [%]
MULTI GAP 2010 39 52 0.000
PLUS Program 30 43 0.011
p = 0.089 p = 0.009
Table II. The mean body mass index values and the
occurrence of hypertension, smoking and diabetes
in the MULTI GAP 2010 basic study and PLUS
Program in the patient groups treated by GPs and
specialists Men Women Value of p
LDL cholesterol level [mmol/l, mean ± SD]
Total 2.76 ±0.95 2.93 ±1.02 0.001
MULTI GAP 2010 2.81 ±0.96 2.99 ±1.03 0.001
PLUS Program 2.58 ±0.89 2.73 ±0.96 0.091
Body mass index [kg/m2, mean ± SD]
Total 29.2 ±4.8 28.9 ±5.2 0.227
MULTI GAP 2010 29.2 ±4.8 28.9 ±5.2 0.233
PLUS Program 29.3 ±4.6 29.1 ±5.6 0.753
Hypertension [%]
Total 90 91 0.372
MULTI GAP 2010 90 91 0.517
PLUS Program 90 92 0.482
Smoking [%]
Total 36 20 0.000
MULTI GAP 2010 35 20 0.000
PLUS Program 40 21 0.000
Diabetes mellitus [%]
Total 48 44 0.056
MULTI GAP 2010 49 47 0.405
PLUS Program 45 32 0.009
Table III. The distribution of LDL cholesterol level,
body mass index and the occurrence of hyper -
tension, smoking and diabetes according to gender
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Figure 4. The relationship between the attainment
of 2.5 mmol LDL-cholesterol level and the patients
compliance in the MULTI GAP study
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infarction [5]. These results give a kind of
encouragement to those who are engaged in
prevention and to health policy, since they show
that CVD is preventable and that a greater role
should be given to achieving changes in lifestyle. 
The STENO-2 study compares the importance of
treatment of 3 major risk factors (hyperlipidaemia,
hypertension and diabetes mellitus) in the
development of cardiovascular events in type 2
diabetic patients. The 13.3-year follow-up of 80
patients receiving intensive therapy and 80
receiving standard therapy confirmed the primacy
of intensive risk factor treatment and of a multi -
factorial approach [12, 13]. In the study there was
a significant difference in attaining target values of
the different risk factors. The best ratio was that of
cholesterol, followed by hypertension and HbA1c. 
The analysis of Yudkin et al., based on results of
various intervention and epidemiological studies,
compares the number of patients needed to treat
for the prevention of one event (NNT = number
needed to treat) with the same risk factors. With 
1 mmol/l cholesterol reduction 59.5 patients, with
10/5 mmHg blood pressure reduction 61.8, and with
0.9% reduction in HbA1c 140.3 patients have to be
treated for 5 years to prevent one fatal or non-fatal
heart attack or sudden cardiac death [14]. The
STENO-2 study and Yudkin's meta-analysis
demonstrate that the incidence of cardiovascular
events can be influenced the best by reducing the
cholesterol level; this is the activity in which the
target levels would be the easiest to attain. 
The key element in the prevention guidelines is
the adequate reduction of lipids in stable and
unstable ischaemic conditions [15]. The last 1.5-2
decades have resulted in the appreciation of lipid-
lowering therapy in the developed countries and
this, with some delay, arrived in Hungary as well.
The EUROASPIRE studies also showed that in
patients suffering from CHD the treatment of all
risk factors improved, but the changes in lipid goal
achievements were extremely good [16, 17]. 
The extent of the lipid-lowering therapy is
determined by the goal values depending on the
risk categories. In its spreading in Hungary the
consensus conference held every 2 years has had
notable achievements which help to keep the topic
of prevention before the public eye. Moreover, the
results of conferences are constant subjects of
continuous medical education, and publications
about the consensus are constant themes in the
medical journals. Currently the recommendations
of the 4th Hungarian Cardiovascular Consensus
Conference are considered as standards in
cardiovascular prevention [9]. 
The publication of outstanding results of the
clinical studies performed with statins also
contributes to applying more frequently the
representatives of this class of drugs in Hungary
as well. Data of systematic surveys of recent years
show that the LDL-C attainment rate in patients
with high cardiovascular risk is continuously
increasing. The increased activity of pharmaceutical
companies also played an important role in this,
on one hand by promoting and propagating the
principles of prevention and the results of
consensus conferences, and on the other hand by
presenting lipid-lowering drugs, including generic
statins, at low prices to the colleagues. It has been
proved that lipid-level reduction plays a consi -
derable role in the improvement of cardio vascular
mortality in Hungary [18] but due to the absence
of accurate data its extent cannot be given. The
increasing use of combination therapy also
contributes to these positive results. In the MULTI
GAP 2010 study the application rate of combination
treatment was 10%. However, it should be noted
that in patients of doctors properly educated by
the PLUS Program the administration of
combination therapy was more frequent (22%),
which resulted in a significantly greater LDL-C
target attainment (Figure 5). 
Results of MULTI GAP 2010 taking into account
also the trends of previous years show that the
upward trend has been broken; the significant
improvement observed initially each year is now
hardly noticeable. Li et al. in the population-wide
representative National Health and Nutrition
Examination Survey conducted in the U.S. with
a large number of individuals between 1999 and
2006 found a decrease of the LDL-C levels in men
from 3.25 ±0.03 to 3.02 ±0.02, and that in women
from 3.11 ±0.03 to 2.98 ±0.03 mmol/l (p < 0.001)
[19]. In Hungary, the observed decrease during the
same period (0.77 for GPs, 0.50 mmol/l for spe -
cialists) was significantly higher, but it should not
be forgotten that the latter record came from high-
risk patients treated by lipid-lowering drugs, and
yet it is noteworthy that the U.S. average LDL-C level
is essentially similar to that of high-risk, treated
patients of Hungary. Farzadfar et al., analysing
global trends, found (not in high cardio vascular risk
patients) in higher-income countries (Western
Europe, North America and Australia) a 0.2 mmol/l
decrease, and in Eastern and Central Europe 
a 0.2 mmol/l decrease in LDL-C level during
a decade [20]. 
A favourable change in the frequency of risk
factors causes a significant reduction in cardio -
vascular mortality [21]. According to the results of
the LTAP study, the achievement rate of LDL-C
target levels rose in 9 countries on average from 
18 to 67% in 10 years [22]. The Hungarian trends
are improving as well, but the results are 
less favourable in international comparative terms
[15, 23, 24].
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In 2010, besides MULTI GAP, the standard quality
measurement of lipid-lowering therapy, a new trial
was carried out in which a smaller group of doctors
received a special education named the Plus
Program. The results proved that education of GPs
and specialists can boost further improvement of
reaching the target level, i.e. a better knowledge of
principles and practices of prevention, and
application of the lipid-lowering computer program
results in the improvement of treatment. The
importance of education is also emphasized in the
publication of Katsiki et al. [25]. 
It is well known that women have less favourable
indicators of cardiovascular prevention [26]. Lipid
lowering and achieving the targets in Hungary seem
to be no exception. Women's LDL-C level was higher
by 6.2%, 0.17 mmol/l. The trend was similar among
male and female patients of the PLUS Program (0.15
mmol/l is not a statistically significant difference
due to the small sample size), which means that
a better understanding of the principles of
prevention itself does not lead to more favourable
rates. Perhaps the indicators would improve if the
training drew more attention to careful treatment
of women.
The administration of ezetimibe results in
a lower LDL cholesterol level [27]. Our results
demonstrate that the frequent use of combination
therapy helps to achieve the target levels 
(Figure 5). In patients reaching the target values,
higher statin doses were applied (undoubtedly, the
difference was not statistically significant).
The effectiveness of drug therapy largely
depends on the therapeutic cooperation of the
patients [28]. The meta-analysis of Simpson et al.
found a correlation between therapeutic adherence
and the occurrence of clinical events, including
deaths [29]. Rasmussen et al. studied the relation -
ship of long-term survival and evidence-based
pharmacotherapy in post-infarction patients. More
than 31 thousand patients were followed and it was
concluded that good adherence to statins also led
to a reduction in mortality [30]. In our study, we
found a linear correlation between the patients’
cooperation in compliance of drug taking and
achievement of the LDL-C target value (Figure 4).
Between the good and bad compliance group there
was a 17% difference in the target level attainment
rate, which in the long term would evidently cause
a difference in the occurrence of clinical events. 
Overall, the 2010 MULTI GAP study showed that
the improvement of quality of lipid-lowering therapy
in Hungary came to a stop. The results of the PLUS
Program suggest that the continuous training of
doctors is the key to further improvement. This
training must draw attention to women's increased
risk and the need for their more careful treatment.
Achievement of target values is favourably
influenced by improved patient compliance. Each
consultation between doctor and patient should
draw the patient's attention to the fact that the
effectiveness of lipid-lowering therapy will deliver
the expected anti-atherosclerotic results and
lowering effect on cardiovascular events only if
medication compliance is appropriate. Stricter
follow-up of patients also improves the therapeutic
collaboration. Every lipid-level control should include
a revision of the therapy. Our study also confirmed
that by applying higher doses of statins together
with combination treatment a greater lipid-lowering
effect and better target level attainment could be
achieved. 
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